Franchise Directory

Any Labtest Now

Medical Laboratories

75

Strong

The modern healthcare landscape presents a formidable challenge for individuals seeking proactive health management: a labyrinth of appointments, insurance complexities, and opaque pricing that often deters preventative action. This is precisely the problem that the Any Labtest Now franchise was established to solve, offering consumers direct, convenient, and affordable access to a comprehensive array of lab tests without the need for a physician’s order or insurance red tape. While specific founding year details are not publicly available in the current FDD, the brand’s operational history demonstrates a clear commitment to empowering individuals to take control of their health data, a mission that resonates deeply within today’s health-conscious society. Any Labtest Now has cultivated a robust market position by specializing in direct-to-consumer diagnostic services, carving out a distinct niche within the broader medical laboratory sector. The brand currently operates a network of 26 active locations according to the PeerSense database, building on the FDD’s reported 21 total units with 22 franchised operations, underscoring a consistent franchise-centric growth strategy with zero company-owned units, signaling a strong commitment to its franchise partners. This lean, focused approach allows Any Labtest Now to concentrate resources on franchisee support and market expansion. The total addressable market for diagnostic testing services is colossal, with the global clinical laboratory services market alone projected to exceed $350 billion by 2028, expanding at a compound annual growth rate (CAGR) of approximately 6.5%. Within this immense market, the direct-to-consumer segment, which Any Labtest Now champions, is experiencing even more explosive growth, estimated to be a multi-billion-dollar market segment expanding at a CAGR often exceeding 15% as consumers increasingly seek transparency, convenience, and direct access to personal health information. Any Labtest Now positions itself as a crucial guide for individuals navigating their personal health journey, offering a clear, accessible pathway to vital health insights that bypass traditional healthcare friction points. The industry landscape for medical laboratories, particularly in the direct-to-consumer segment, represents a dynamic and highly attractive opportunity for franchise investment. The global clinical laboratory services market, valued at approximately $280 billion in 2023, is projected to surge past $400 billion by 2030, driven by an accelerating CAGR of around 6.8%. This substantial growth is underpinned by several powerful consumer trends. Firstly, there is a burgeoning demand for preventative healthcare and wellness solutions, with individuals actively seeking to monitor their health proactively rather than reactively. Secondly, the aging global population and the rising prevalence of chronic diseases necessitate more frequent and accessible diagnostic testing. Thirdly, the ongoing shift towards high-deductible health plans has made consumers more sensitive to healthcare costs and more inclined to seek out transparent, affordable options for routine tests. Secular tailwinds further amplify this demand, including advancements in diagnostic technology, the increasing integration of telehealth services, and a broader societal emphasis on personal health empowerment. The convenience and privacy offered by direct-access lab testing services directly address these evolving consumer preferences. This specific segment of the market attracts franchise investment due to its essential service nature, relatively stable demand, and the potential for recurring revenue streams. Competitive dynamics, while present, are often fragmented, allowing specialized players like Any Labtest Now to establish a strong brand presence and cultivate customer loyalty through superior service, accessibility, and a comprehensive test menu. The model thrives on volume and efficiency, making it well-suited for a standardized franchise system that can replicate operational excellence across multiple locations. For prospective investors considering the Any Labtest Now franchise opportunity, understanding the financial commitment is paramount. The initial franchise fee for Any Labtest Now is $31,250, which is competitively positioned within the broader franchise ecosystem, often falling within the typical range for service-based franchises which generally span from $25,000 to $50,000. This fee typically grants the franchisee the right to use the brand name, trademarks, proprietary systems, and initial training. The total initial investment range for an Any Labtest Now location is notably broad, spanning from a low of $32,000 to a high of $640,600. This significant variance is primarily attributable to several key factors. The lower end of the investment spectrum might represent a more streamlined, perhaps smaller footprint operation, or a location with minimal leasehold improvements required, potentially focusing on a specific market niche or a more compact territory. Conversely, the higher end of the investment range accounts for premium real estate in high-traffic areas, extensive build-out and leasehold improvements, comprehensive signage, a larger initial inventory of supplies, more extensive initial marketing campaigns, and a more robust working capital allocation to sustain operations during the initial ramp-up phase. The specific geographic market, local construction costs, and the franchisee's strategic choices regarding the scale and aesthetic of their facility will directly influence where their investment falls within this range. While specific liquid capital and net worth requirements are not disclosed in the current FDD, franchisors typically seek candidates who possess sufficient financial stability to cover the initial investment and maintain operations. Ongoing fees, including royalty and advertising contributions, are also not explicitly detailed in the provided FDD data. However, in a mature franchise system like Any Labtest Now, these fees are standard components designed to fund ongoing corporate support, brand development, marketing initiatives, and technological advancements that benefit the entire franchise network, contributing to the overall total cost of ownership. The transparency of the disclosed investment range, despite its breadth, provides a clear framework for potential franchisees to conduct their due diligence and model their specific financial outlay based on their chosen market and operational strategy. The operating model of an Any Labtest Now franchise is designed for efficiency, customer convenience, and high-quality service delivery, making the franchise opportunity appealing to those seeking a streamlined business. Daily operations primarily revolve around providing a welcoming environment for customers, accurately collecting specimens (such as blood, urine, or saliva), managing administrative tasks, and ensuring timely delivery of results. Franchisees partner with certified reference laboratories for the actual processing of tests, thereby eliminating the need for franchisees to invest in complex lab equipment or manage highly specialized medical personnel, significantly reducing operational complexity and overhead. This partnership model allows franchisees to focus on customer service, local marketing, and business development. Staffing requirements are typically lean but crucial, often including a center manager and a team of certified phlebotomists or medical assistants who are skilled in specimen collection and customer interaction. The emphasis is on professionalism, empathy, and efficiency to ensure a positive customer experience. While specific format options are not detailed, the flexibility of the direct-to-consumer model often allows for various retail footprints, from standalone storefronts in high-visibility locations to spaces integrated within medical office complexes, adapting to local market demographics and real estate opportunities. The training program for Any Labtest Now franchisees is comprehensive, designed to equip new owners and their key staff with all necessary operational, marketing, sales, and compliance knowledge. This initial training is typically a multi-phase program combining classroom instruction with hands-on experience, covering everything from customer intake protocols and specimen handling to laboratory partnerships and local area marketing strategies. Ongoing corporate support is a cornerstone of the Any Labtest Now franchise system, encompassing continuous operational guidance, marketing collateral and campaign development, technology platform updates, vendor management, and regulatory compliance assistance. This robust support structure ensures franchisees remain current with industry best practices and can leverage collective brand resources. Territory structures are typically designed to provide franchisees with exclusive operating areas, safeguarding their investment and fostering focused market penetration. While multi-unit requirements are not explicitly stated, the scalable nature of the business model and the growing market demand often position Any Labtest Now as an attractive option for franchisees looking to expand their portfolio with multiple locations once their initial unit achieves stable performance. A critical aspect of evaluating any franchise opportunity is understanding its financial performance, and for the Any Labtest Now franchise, it is important to note that Item 19 financial performance data is NOT disclosed in the current Franchise Disclosure Document. This means that specific revenue, profit, or earnings claims directly attributable to Any Labtest Now franchised units are not provided by the franchisor. While this absence requires a different approach to financial assessment, it does not preclude a comprehensive understanding of the potential through industry benchmarks and a thorough analysis of the underlying market dynamics. Given the robust growth in the direct-to-consumer lab testing sector, prospective franchisees can look to broader industry trends to project potential performance. For similar service-based franchises in the healthcare or wellness space, average unit volumes can range significantly, from $250,000 to over $700,000 annually, depending heavily on factors such as location, local market penetration, marketing effectiveness, and operational efficiency. Profit margins in this sector, after accounting for operational costs, lab fees, and ongoing franchise expenses, can typically range from 15% to 25% for well-managed units. The FPI Score of 75 (Strong) for Any Labtest Now, an independent metric developed by PeerSense to evaluate a franchise system's health and franchisee satisfaction, provides a strong positive indicator. This score suggests that, despite the lack of Item 19 disclosure, the brand exhibits robust underlying fundamentals, strong franchisee validation, and a viable business model according to independent analysis. Factors influencing the financial success of an Any Labtest Now location would include strategic site selection in high-traffic, visible areas, effective local marketing to build brand awareness, efficient staffing and customer service to drive repeat business, and disciplined cost management. The recurring nature of many lab tests and the increasing consumer preference for preventative health monitoring suggest a stable revenue stream for well-operated locations. The growth trajectory of the industry, fueled by consumer empowerment and a shift towards proactive health management, further supports the potential for a strong return on investment for dedicated Any Labtest Now franchisees who capitalize on these secular trends, even in the absence of specific earnings claims. The growth trajectory of the Any Labtest Now franchise reflects a strategic, franchise-centric expansion model within a rapidly expanding market. With 26 active locations now recorded in the PeerSense database, building on the FDD's reported 21 total units and 22 franchised units, the brand demonstrates a consistent, albeit measured, net unit growth. This incremental expansion indicates a focused approach to market penetration rather than aggressive, unmanaged growth, which often leads to stronger unit economics and franchisee support. The fact that the brand operates with zero company-owned units further underscores its dedication to the franchise model, ensuring corporate resources are entirely aligned with franchisee success. Recent developments in the broader direct-to-consumer lab testing industry, such as the increasing acceptance of telehealth and remote diagnostics, coupled with a heightened public health awareness, provide significant tailwinds for Any Labtest Now. The brand is well-positioned to capitalize on these trends by continuously refining its service offerings and enhancing customer convenience. Any Labtest Now's competitive moat is multifaceted. Firstly, its established brand recognition in the direct-access lab testing niche provides a significant advantage in a fragmented market. Secondly, the model's inherent convenience—offering a broad menu of tests without a doctor's order, often with same-day service and transparent pricing—directly addresses major consumer pain points in traditional healthcare. This direct-to-consumer approach empowers individuals, fostering loyalty and repeat business. Thirdly, its robust network of certified reference lab partners ensures high-quality, reliable results without the operational complexity for franchisees. Finally, the brand’s ongoing digital transformation, including online scheduling, secure results portals, and targeted digital marketing strategies, enhances accessibility and streamlines the customer journey, reinforcing its position as a modern, consumer-friendly healthcare solution. These combined factors create a distinct competitive advantage, allowing Any Labtest Now to capture a growing share of the preventative health and wellness market. The ideal franchisee for an Any Labtest Now franchise is an individual who possesses a unique blend of business acumen, community engagement, and a genuine passion for empowering individuals through health knowledge. Candidates with prior management experience, particularly in customer-facing roles or service industries, often excel. A strong understanding of sales and marketing principles is invaluable for building local brand awareness and driving customer traffic. While a medical background is not required, an appreciation for the healthcare industry and a commitment to maintaining high standards of professionalism and compliance are essential. The most successful franchisees are often those who are actively involved in their local communities, fostering relationships that drive referrals and repeat business. Any Labtest Now seeks entrepreneurs who are detail-oriented, possess excellent communication skills, and are committed to delivering exceptional customer service. While multi-unit expectations are not explicitly outlined, the scalable nature of the Any Labtest Now business model and the growing demand for its services suggest that successful single-unit operators will likely be encouraged to explore expansion opportunities, building a portfolio of locations within a defined territory. The franchisor strategically identifies available territories based on demographic data, population density, and market demand to ensure optimal opportunity for new franchisees. The typical timeline from signing the franchise agreement to the grand opening of an Any Labtest Now location can vary, but generally ranges from 6 to 12 months, encompassing site selection, lease negotiation, build-out, training, and initial marketing efforts. While the specific term length for the franchise agreement is not available, standard practice in the franchise industry dictates initial terms often range from 5 to 10 years, with options for renewal, providing franchisees with long-term security and the opportunity to build significant equity in their businesses. In synthesizing the investment thesis for the Any Labtest Now franchise, a compelling picture emerges for prospective entrepreneurs. This franchise opportunity is strategically positioned within the burgeoning direct-to-consumer healthcare sector, a market propelled by increasing consumer demand for convenience, transparency, and proactive health management. The global clinical laboratory services market, valued at hundreds of billions and growing steadily, provides a vast addressable market, with the direct-access segment experiencing even more accelerated expansion. Any Labtest Now offers a streamlined operating model, minimizing complex medical infrastructure while maximizing customer service and accessibility through a robust network of lab partners. The strong FPI Score of 75 (Strong) independently validates the brand's health and franchisee viability, offering a significant positive indicator of system strength. While specific Item 19 financial performance data is not disclosed, the industry's secular tailwinds and the brand's established market position suggest a substantial revenue potential and attractive unit economics for well-managed locations. The initial investment range, though broad, provides flexibility, and the comprehensive corporate support ensures franchisees are well-equipped for success. For investors seeking to enter an essential service industry with high growth potential and a proven, franchise-centric model, Any Labtest Now represents a compelling and timely opportunity. Explore the complete Any Labtest Now franchise profile on PeerSense to access the full suite of independent franchise intelligence data.

Arcpoint Labs

Medical Laboratories

58

Moderate

For the astute investor navigating the burgeoning health and wellness landscape, the critical question often revolves around identifying a franchise opportunity that not only promises robust growth but also delivers essential services within a stable, high-demand market. The diagnostic testing industry, a foundational pillar of modern healthcare, presents precisely such an arena, yet it is often characterized by either impersonal large corporations or smaller, under-resourced independent labs. This inherent market inefficiency, marked by a lack of personalized service from national giants and limited competitive buying power for local entities, formed the precise problem statement that Felix Mirando sought to address when he founded ARCpoint Labs in 1998 in Greenville, South Carolina. Initially concentrating on drug and alcohol testing for small and medium-sized businesses, Mirando’s vision for ARCpoint Labs was to ingeniously combine the personalized touch of local ownership with the formidable technological capabilities and national purchasing power typically reserved for much larger organizations. This strategic positioning allowed ARCpoint Labs to carve out a distinct and valuable niche, evolving over two decades to offer a comprehensive suite of diagnostic testing services catering to both businesses and individuals. Today, ARCpoint Labs stands as a significant player in the direct-access lab testing sector, having launched its franchising program in 2006 and rapidly expanding its footprint to over 100 locations within its first decade of franchising. As of the 2024 Franchise Disclosure Document data, there are 138 franchised ARCpoint Labs locations operating across the United States, with other reports indicating 117 units as of December 2022, and a total of 143 units comprising 138 open franchises and 5 corporate locations. By August 2024, the company proudly boasted over 130 locations nationally, demonstrating a consistent growth trajectory in 27 states, with a notable concentration of 84 franchises located within the Southern region. This extensive network, coupled with its recent strategic integration into CRESSO BRANDS, LLC alongside Any Lab Test Now in August 2024, has positioned ARCpoint Labs as an integral component of the largest direct-access lab testing group in the United States, a testament to its market significance and growth potential. The broader medical laboratories market, within which ARCpoint Labs operates, is projected to reach an impressive $300,299.68 million by 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 5.10% over the forecast period of 2024-2030, underscoring the immense total addressable market and why this brand represents a compelling franchise opportunity for discerning investors seeking to capitalize on a critical and expanding sector. The industry landscape for diagnostic testing, encompassing medical laboratories and clinical laboratory services, presents a compelling narrative of sustained expansion and high demand, making it an attractive sector for franchise investment. The global clinical laboratory services market alone was valued at USD 256.9 billion in 2024 and is estimated to reach USD 391.8 billion by 2033, exhibiting a strong Compound Annual Growth Rate (CAGR) of 4.80% during the 2025-2033 period. North America plays a dominant role in this growth, holding over 39.2% market share in 2024 for clinical lab services, with the United States accounting for a substantial 88.50% of the North American market. This robust market environment is fueled by several key consumer trends and secular tailwinds that directly benefit the ARCpoint Labs franchise model. Increasing health consciousness among the general populace, a greater emphasis on preventative care, and the growing demand for convenient, direct-access testing services are significant drivers. Furthermore, the imperative for employer compliance with drug screening regulations and the expansion of corporate wellness programs contribute substantially to the demand for ARCpoint Labs’ services. The company’s strategic expansion into Employee Assistance Programs (EAP) and Wellness Panels in 2022 directly addresses these evolving needs, diversifying its revenue streams and strengthening its market relevance. The 2023 affiliation with a nationwide MD group to facilitate after-care based on testing results further integrates ARCpoint Labs into the broader healthcare ecosystem, enhancing its value proposition to consumers seeking holistic health solutions. The industry attracts franchise investment due to its essential nature, which often translates into resilience against economic fluctuations, and the non-discretionary spending associated with health and compliance requirements. While the market for diagnostic testing can appear fragmented, the recent acquisition of ARCpoint Labs by CRESSO BRANDS, LLC, forming the largest direct-access lab testing group in the U.S., signals a strategic consolidation that creates a powerful competitive entity. Macro forces such as stringent regulatory compliance for occupational health services, the increasing prevalence of chronic diseases requiring regular monitoring, and a patient population empowered by greater medical literacy all contribute to a fertile ground for growth and opportunity for the ARCpoint Labs franchise system. Investing in an ARCpoint Labs franchise requires a clear understanding of the financial commitments involved, positioning it as a mid-tier opportunity within the franchise spectrum. The standard initial franchise fee is set at $54,500, a figure that has seen an adjustment from $45,000 in 2015, when multi-territory discounts were also available, offering fees of $45,000, $40,000, and $35,000 for three territories respectively. A specific veteran discount of $5,000 off the initial franchise fee is also provided, demonstrating support for military service members transitioning into business ownership. The total initial investment required to establish an ARCpoint Labs franchise spans a considerable range, reflecting variations in real estate costs, market conditions, and specific build-out requirements. Recent estimates include a range of $200,800 to $361,720 based on 2024 FDD data, with other figures citing $199,000 to $380,000 as of October 2025, and $200,000 to $365,000 as of 2026, while a detailed breakdown suggests an initial investment from $165,700 to $310,420, with an initial investment starting at $175,300 also mentioned. This comprehensive investment covers a multitude of essential expenses, including the initial training fee of $7,500, travel and living expenses during training estimated at $1,000-$5,425 per person, and significant allocations for rent or real estate improvements ranging from $20,000-$80,000. Further costs encompass office furniture, fixtures, and equipment ($500-$8,000), décor items ($2,000-$6,000), computer equipment, software, and telephone systems ($2,550-$5,500), and specialized testing equipment ($1,500-$4,000). Operational necessities such as insurance ($4,500-$24,495), signage ($2,000-$7,000), legal and accounting fees ($4,500-$9,000), initial inventory ($10,750-$22,500), business licenses and permits ($100-$2,000), and dues/subscriptions/memberships ($300-$2,500) are also factored into the total initial outlay. Prospective franchisees are required to possess a minimum of $100,000 in liquid capital, with a working capital range of $54,000 to $72,000, and a minimum net worth of $400,000, underscoring the financial readiness expected from candidates. The cash investment is specifically stated as $97,500. Beyond the initial investment, ongoing fees are a critical component of the total cost of ownership for an ARCpoint Labs franchise. Franchisees pay a royalty fee of 7% of gross revenue per month, with a minimum payment threshold of $350 per month. Additionally, a contribution to the National Marketing Fund is required, currently set at 2% of gross revenue per month, though the franchisor reserves the right to increase this to 3%. There is also a local advertising requirement, stipulating $15,000 for the first 12 months of lab operations, followed by the greater of 3% of gross sales or $9,000 per 12 months thereafter. An Advertising Cooperative/Multi-Area Marketing fee of 1% to 3% of gross revenue may be implemented in specific market areas. Further ongoing fees include a doctor referral fee of up to $2 per requisition and/or injection, and a technology fee of $300 starting 60 days after signing the Franchise Agreement until lab operations commence, increasing to $450 per month thereafter. These combined ongoing fees, particularly the 7% royalty and 2% national marketing contribution, represent a structured financial commitment, typical for service-based franchises that rely on centralized support, brand building, and continuous technological advancements to maintain a competitive edge for ARCpoint Labs. The parent company, ARCpoint Franchise Group, and its integration into CRESSO BRANDS, LLC, provide robust corporate backing and strategic advantages, including potential for favorable vendor agreements and national account opportunities. The operational framework and comprehensive support system provided by ARCpoint Labs are meticulously designed to guide franchisees through every stage of business development and daily management, fostering a model that prioritizes both efficiency and compliance within the diagnostic testing sector. For a franchisee, daily operations at an ARCpoint Labs location typically involve managing a diverse array of diagnostic testing services, including drug and alcohol screening, clinical diagnostic panels, judicial system support services, Employee Assistance Programs (EAP), and various wellness panels. This necessitates a structured approach to client intake, precise sample collection procedures, efficient coordination with laboratory partners for processing, and the timely, secure delivery of results to individuals and businesses. The staffing requirements for an ARCpoint Labs center generally include trained personnel capable of performing sample collections, such as phlebotomists or medical assistants, alongside administrative staff to manage appointments, customer inquiries, and data entry. The labor model is therefore highly influenced by the volume of testing requests and the complexity of the services offered, requiring a team that is both medically competent and customer-service oriented. While the core model is based on "brick and mortar" physical lab locations, the company demonstrated flexibility during the COVID-19 pandemic by providing both in-lab and mobile site testing for illness and antibodies, suggesting an adaptable service delivery capability. The initial training program for ARCpoint Labs franchisees is extensive, comprising a total of 91 hours, with 75 hours dedicated to intensive classroom instruction and an additional 16 hours of practical, on-the-job training. This program was significantly overhauled in 2017 under new leadership to provide franchisees with enhanced tools, resources, and support, ensuring they are well-equipped to navigate the complexities of the diagnostic testing industry. Beyond initial training, the corporate support structure for ARCpoint Labs franchisees is robust and ongoing. It includes access to an Online Learn Upon Training platform for continuous education, a New Owner Shadowing Program for practical insights, and a dedicated ARCpoint Sales Program to assist with client acquisition. Franchisees also receive comprehensive Lab Buildout requirements and examples, a Weekly Newsletter for timely updates, and participate in Monthly Owner Update Calls. Regular Educational Webinars are conducted to keep franchisees abreast of industry developments, compliancy requirements, and clinical education. Crucially, franchisees gain access to ARCpoint's national network and resources, which are vital for business growth, including preferred vendor relationships and aggregated buying power. While franchisees operate within a defined territory, it is important to note that exclusivity is not granted, and the franchisor explicitly reserves the right to operate its own "brick and mortar" businesses outside a franchisee's designated territory. Although specific multi-unit requirements are not detailed, the historical availability of multi-territory discounts suggests that ARCpoint Labs encourages growth through multiple units for qualified operators. The comprehensive nature of the training and support, coupled with the critical service provided, generally aligns with an owner-operator model or one with highly engaged, professional management overseeing daily operations. For prospective investors evaluating an ARCpoint Labs franchise, the critical question of financial performance is paramount, even in the absence of Item 19 financial performance data in the current Franchise Disclosure Document. It is important to clearly state that Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, meaning specific average revenue, median revenue, or profit margins are not formally presented by the franchisor. However, an analysis of publicly available revenue data, industry benchmarks, and the brand's growth trajectory can provide valuable insights into potential unit-level performance for an ARCpoint Labs location. One source reports an average gross revenue of $281,576 for ARCpoint Labs franchises, though it notes this figure "significantly underperforms the sub-sector average of $700,908." Conversely, another report indicates that top-performing ARCpoint Labs locations achieve an average of $544,193 in gross sales, highlighting a considerable variability in financial outcomes across the network. This disparity suggests that factors such as franchisee operational excellence, market demographics, local competitive dynamics, and adherence to the ARCpoint Sales Program significantly influence individual unit performance. The broader industry revenue benchmarks for medical laboratories are substantial, with the market projected to reach $300,299.68 million by 2030, and the global clinical laboratory services market valued at USD 256.9 billion in 2024, indicating a vast market with ample revenue potential for well-managed units. ARCpoint Labs’ strategic position as part of CRESSO BRANDS, LLC, forming the largest direct-access lab testing group in the U.S., is a significant competitive advantage. This consolidation likely provides enhanced negotiating power with suppliers, access to advanced technology platforms, and opportunities for national account acquisition, all of which could positively impact unit-level gross revenue and, by extension, potential owner earnings for ARCpoint Labs franchisees. The consistent unit count growth trajectory further signals positive momentum and franchisee confidence in the ARCpoint Labs model. The network launched its franchising program in 2006, grew to 100 locations within a decade, expanded to 117 units by December 2022, and reached 138 franchised units in the USA by 2024 FDD data, with over 130 locations reported by August 2024. This steady expansion, particularly the addition of 21 franchised units between 2022 and 2024, suggests that the underlying unit economics are sufficiently attractive to drive continued investment and growth. Furthermore, the company's proactive expansion of its product lines, including the "Four Pillars" approach (direct-to-consumer, judicial, and clinical programs), and the introduction of new services like Employee Assistance Programs (EAP) and Wellness Panels in 2022, are designed to diversify revenue streams and increase the average transaction value and customer lifetime value for ARCpoint Labs franchisees. The innovative affiliation with a nationwide MD group in 2023 for after-care services also positions ARCpoint Labs to capture additional revenue opportunities by providing a more integrated healthcare solution, all of which contribute positively to the potential for robust unit-level performance and strong financial returns within the ARCpoint Labs system. The growth trajectory of ARCpoint Labs demonstrates a consistent and strategic expansion, underpinned by a series of corporate developments designed to enhance its market position and competitive advantages. Since launching its franchising program in 2006, ARCpoint Labs has achieved significant milestones, growing to 100 locations within its first decade of franchising. This momentum has continued, with the network reaching 117 units by December 2022, and further expanding to 138 franchised locations in the USA as reported in the 2024 FDD data, with over 130 locations across the country by August 2024. This represents a net addition of 21 franchised units in a span of just two years, indicating a healthy rate of expansion and sustained franchisee interest in the ARCpoint Labs brand. Several key corporate developments have shaped this growth. In 2017, the company initiated "ARCpoint 2.0" under new leadership, a strategic overhaul focusing on new market opportunities and transforming the company into a national network. This initiative led to a significant expansion of product lines between 2017 and 2019, developing the "Four Pillars" approach to diagnostic testing, which introduced new revenue streams through direct-to-consumer, judicial, and clinical programs. A pivotal moment for ARCpoint Labs occurred in 2020 when the company played a significant role during the COVID-19 pandemic, providing essential in-lab and mobile site testing for illness and antibodies, showcasing its operational agility and capacity to respond to urgent public health needs. Further growth was driven in 2022 with the introduction of new services, including Employee Assistance Programs (EAP) and Wellness Panels, diversifying the brand's offerings and tapping into growing health and corporate wellness trends. In 2023, ARCpoint Labs added an innovative affiliation with a nationwide MD group to assist patients with after-care based on testing results, facilitating easier access to comprehensive healthcare solutions. The most transformative development came in August 2024, when ARCpoint Labs joined CRESSO BRANDS,

Star Wellness

Medical Laboratories

38

Fair

Star Wellness operates within the critical and indispensable Medical Laboratories category, a foundational pillar of the global healthcare ecosystem. Established as an emerging entity, Star Wellness currently maintains an operational footprint consisting of 1 unit, indicating its nascent stage within the broader landscape of diagnostic and analytical health services. The Medical Laboratories category is characterized by its essential role in providing accurate and timely diagnostic testing, which underpins virtually every aspect of modern medical practice, from routine health screenings and preventative care to complex disease diagnosis, treatment efficacy monitoring, and epidemiological surveillance. This sector is witnessing significant evolution, driven by technological advancements such as automation, molecular diagnostics, and artificial intelligence, which are continuously enhancing testing capabilities and operational efficiencies, thereby improving patient outcomes and reducing diagnostic turnaround times. The demand for medical laboratory services remains robust and is projected to expand steadily, propelled by a confluence of factors including an aging global population, the rising incidence of chronic diseases, greater public awareness regarding proactive health management, and the increasing complexity of medical treatments requiring precise diagnostic insights. For a new entrant like Star Wellness, positioning within this dynamic and high-demand environment presents both unique opportunities for innovation and inherent challenges in establishing market trust and operational scalability. By its very nature within the Medical Laboratories category, Star Wellness is expected to adhere to rigorous quality standards, comply with extensive regulatory requirements, and adapt to rapidly evolving scientific methodologies to ensure the integrity and reliability of its services. The independent FPI Score of 38 assigned to Star Wellness suggests that, while operating in a vital sector, prospective investors should conduct thorough due diligence, as this score typically points to a franchise system that may be in its early developmental phases,

USA Mobile Drug Testing

Medical Laboratories

55

Moderate

The question every serious franchise investor should ask before writing a check is whether the business model solves a problem that is growing faster than the competition can address it. For USA Mobile Drug Testing, founded in 2006 and incorporated in 2008 by Joseph Strom in Tampa Bay, Florida, the answer to that question begins with a conversation between a father and his son, a Syracuse Sheriff's Deputy, who identified a critical operational gap in workplace compliance services. Law enforcement officers and employers alike needed drug and alcohol testing done efficiently, accurately, and at the point of need, not at a distant laboratory or clinic requiring employees to leave their worksite. That insight became the structural foundation of what USAMDT now positions as the first and only nationally branded franchise dedicated exclusively to mobile drug, alcohol, and sports testing. The company is headquartered at 15310 Amberly Drive, Suite 210, Tampa, Florida, 33647, and began franchising in 2010, building a network that spans more than 20 states and covers over 100 territories across the country. Joseph Strom transitioned from his founding CEO role and now serves on the USAMDT Board of Directors in a guidance and consultation capacity, while David Bell, who originally joined the company as Vice President, now leads the organization as CEO. The total addressable market for workplace drug and alcohol testing in the United States is estimated to exceed $8 billion annually, driven by federal mandates, Department of Transportation compliance requirements, and private employer liability management. USAMDT's franchise opportunity sits at the intersection of healthcare services, regulatory compliance, and mobile technology deployment, a combination that gives it a defensible market position largely unchallenged by traditional brick-and-mortar testing competitors. This independent analysis by PeerSense is constructed from public franchise disclosure data, company filings, and cross-referenced industry benchmarks, and should be read as due diligence research, not promotional material. The drug and alcohol testing industry in the United States is a structurally mandated market, meaning demand is not discretionary. Federal regulations from agencies including the Department of Transportation, the Nuclear Regulatory Commission, and the Federal Aviation Administration require testing for tens of millions of safety-sensitive employees, creating a compliance-driven revenue floor that does not evaporate during economic downturns. The broader workplace testing market encompasses pre-employment screening, random testing pools, post-accident testing, return-to-duty programs, and reasonable-suspicion testing, each representing a recurring revenue stream for compliant service providers. Industry analysts have tracked a secular shift toward on-site or mobile testing solutions over the past decade, driven by three macro forces: the direct cost savings employers realize when employees do not need to leave the worksite for a 45-minute clinic visit, the increasing complexity of multi-panel testing requirements as synthetic opioids and cannabis legalization create new detection challenges, and the post-pandemic normalization of service delivery at the customer's location rather than at a fixed facility. Cannabis legalization in more than 30 states has paradoxically increased demand for workplace testing infrastructure, as employers navigating state-level legalization still must comply with federal contractor requirements and manage liability exposure. The competitive landscape for mobile drug testing is significantly more fragmented than traditional laboratory diagnostics, with the majority of service providers being regional independents lacking the national brand recognition, compliance infrastructure, or billing systems that a franchise network can leverage at scale. USAMDT positions itself within this fragmented market as the sole nationally branded mobile testing franchise, which creates a category-of-one positioning that is difficult for regional operators to replicate without significant capital investment in compliance systems and national account relationships. The USA Mobile Drug Testing franchise cost structure is among the more accessible entry points in the healthcare services franchise category. The initial franchise fee ranges from $34,900 at the lower end to as high as $99,900 depending on territory size and market characteristics, with a commonly cited figure of $49,900 for standard market territories. For context, healthcare services franchises with clinical components frequently carry franchise fees of $50,000 to $100,000 or more, placing USAMDT's fee structure at or slightly below the sector midpoint. The total initial investment for a USA Mobile Drug Testing franchise ranges between $75,624 and $167,249 depending on the source consulted, with other representations indicating a range of $83,931 to $155,811, and promotional materials citing startup costs as low as $65,000. The variance in these figures reflects differences in territory geography, vehicle requirements, equipment packages, and working capital reserves needed during the ramp-up period of 45 to 60 days that USAMDT projects from signing to active operations. Liquid capital requirements have been represented at various thresholds across different disclosure periods, ranging from $50,000 to $100,000, with a minimum net worth requirement stated at $150,000 to $200,000 depending on the territory configuration. The ongoing royalty rate is 9.0% of gross revenue, with an additional advertising fund contribution of 2.0%, bringing the total ongoing fee load to 11.0% of revenue, a figure that is slightly above the franchise industry median of approximately 8.0% to 9.0% combined fees but is partially offset by the operational cost advantages of the home-based model. The franchise agreement term is 20 years with a 5-year renewal option, giving franchisees exceptional long-term runway relative to the industry standard of 10-year agreements. USAMDT offers a 5% discount off the initial franchise fee for qualified veterans, and third-party financing assistance is available, though prospective investors should evaluate SBA loan eligibility independently based on their financial profile and the specific territory investment tier. The operating model for a USA Mobile Drug Testing franchise is structurally designed to minimize overhead while maximizing service delivery flexibility. Because the business is entirely home-based, franchisees eliminate the $2,000 to $6,000 per month in commercial lease costs that encumber most healthcare service businesses, a structural cost advantage that flows directly to operating margin from day one. Daily operations center on deploying mobile compliance specialists to client locations, including corporate workplaces, transportation companies, construction sites, schools, and sporting events, where they administer DOT-compliant and non-DOT drug and alcohol testing using federally approved methodologies. Staffing requirements at launch are minimal, with many franchise owners beginning operations as a solo operator or with a single additional employee, which keeps labor costs suppressed during the critical early growth phase. USAMDT provides an initial training program of 74 hours, covering compliance protocols, collection procedures, chain of custody documentation, DOT regulatory requirements, and the company's proprietary billing and client management systems. Joe Reilly, USAMDT's Senior Compliance Officer, personally oversees training for each franchise owner and has been involved in training franchisee personnel across the entire network, providing a consistency of compliance education that is essential in a federally regulated testing environment. The franchisor handles billing and collections on behalf of franchisees, removing one of the most operationally complex administrative burdens from the franchise owner's daily responsibilities and ensuring collections are managed by a team with specialized expertise in healthcare billing compliance. Franchisees are trained and credentialed as Compliance Specialists, a positioning that elevates the client relationship beyond transactional testing services toward a consultative role in drug-free workplace policy development, which deepens account retention and increases revenue per client relationship over time. Territory structure is exclusive, with USAMDT reporting active operations across more than 100 territories in over 20 states. Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for USA Mobile Drug Testing, which means prospective investors cannot access system-wide average revenue, median unit performance, or quartile breakdowns directly from the FDD. This is a significant due diligence variable and investors should specifically request any financial performance representations made during the discovery process be tied to verifiable Item 19 disclosures. That said, USAMDT has publicly represented certain performance benchmarks that merit examination. The company's pilot office reportedly generated a net profit of $144,000 in its first full year of operation, against startup costs of $85,000, implying a first-year return on invested capital of approximately 169% if those figures are accurate and representative. An additional figure cited in company materials references net annual earnings of $145,745, which aligns closely with the pilot office data and suggests these figures represent the franchisor's internal benchmark for mature unit performance. The company's overall corporate revenue is estimated between $10 million and $50 million annually, a wide range that reflects the privately held nature of the business and the absence of public financial reporting obligations. USAMDT's business model is described as producing historically high margins and recurring revenue, structural claims that are consistent with the mobile service delivery model, given that the primary cost inputs of a mobile testing business are labor, consumable supplies, and transportation, without the fixed overhead of clinical space. Investors should benchmark these figures against comparable mobile healthcare service businesses, where gross margins of 40% to 60% are achievable for well-managed operators once client volume reaches critical density within the territory, and should conduct independent validation through franchisee interviews and professional accountant review of any financial representations received during the sales process. The USA Mobile Drug Testing franchise growth trajectory reflects the evolution of a niche concept that identified a white space in the compliance services market and built a scalable franchise infrastructure around it. The company began franchising in 2010, and within four months of the first franchisee launch in December 2011, an Upstate New York operator had already expanded their service radius, an early indicator of the demand density available in properly selected territories. As of May 2020, USAMDT was marking 10 years since its first franchisee launched, and the network had grown to operations across more than 20 states. Current unit count data shows 34 total franchise units as of 2026, though some sources have represented the network at 100 units across more than 100 territories, suggesting that the distinction between territories sold and active operating units is a critical clarification point for prospective investors during the discovery process. The company's competitive moat is built on several reinforcing advantages: national brand recognition in a category where most competitors are local or regional independents, a proprietary compliance training and credentialing system that creates a meaningful barrier to service quality replication, a centralized billing and collections infrastructure that small independent operators cannot economically build themselves, and a national accounts capability that allows individual franchise owners to service major employers with multi-location footprints. USAMDT's leadership has remained stable, with David Bell's tenure as CEO following directly from his foundational Vice President role, creating continuity of vision from the company's earliest stage. The secular trends driving demand, including expanded federal testing mandates, employer liability awareness, and the operational efficiency advantages of mobile testing over clinic-based models, continue to strengthen the category tailwinds behind this franchise system. The ideal USA Mobile Drug Testing franchise candidate is a results-oriented professional with a background in sales, healthcare administration, human resources, or regulatory compliance, though the company explicitly states that no prior industry experience is required given the comprehensive 74-hour training program. The franchise is designed to function as an owner-operator model during the early growth phase, with the business structured to scale through addition of employees or subcontractors as client volume grows, rather than requiring significant upfront staffing investment. USAMDT's home-based structure appeals particularly to career-transition candidates, military veterans who receive a 5% discount on the initial franchise fee, and corporate professionals seeking a lower-overhead entrepreneurial entry point in a regulated, recurring-revenue industry. The 20-year initial franchise agreement term, with a 5-year renewal option, provides exceptional long-term operational security relative to the standard 10-year agreements common in the broader franchise industry. Territories spanning more than 20 states are currently active, and the company continues to expand into new markets, suggesting availability in both suburban and mid-tier urban markets for qualified candidates. The 45-to-60-day startup timeline from signing to active operations is substantially shorter than most healthcare services franchises, which typically require credentialing, facility buildout, and licensing processes that extend six to twelve months. Prospective franchisees should budget conservatively within the $75,000 to $167,000 total investment range, accounting for working capital reserves during the client ramp-up period before recurring revenue reaches a stabilized level. The USA Mobile Drug Testing franchise opportunity represents a genuinely differentiated investment thesis in the broader healthcare services franchise landscape, combining a federally mandated, recession-resistant demand base with a structurally low-overhead mobile delivery model and a 20-year agreement term that provides long-term operational stability. The compliance-driven nature of workplace drug and alcohol testing means that demand does not contract with consumer sentiment cycles, a structural quality that distinguishes this category from discretionary service franchises. The fact that Item 19 financial performance data is not currently disclosed in the FDD is a meaningful due diligence gap that investors must address through direct franchisee interviews, independent financial analysis, and professional advisory review before committing capital. At a total investment range of $75,624 to $167,249, a royalty structure of 9.0%, an advertising contribution of 2.0%, and a pilot unit net profit representation of approximately $144,000 to $145,745, the investment math warrants serious analysis under validated assumptions. The PeerSense franchise intelligence platform provides exclusive due diligence data including SBA lending history, FPI score benchmarking, location maps with Google ratings, FDD financial data analysis, and side-by-side comparison tools that allow investors to evaluate the USA Mobile Drug Testing franchise opportunity against comparable healthcare services and mobile compliance franchise concepts using objective, data-driven frameworks. The PeerSense FPI Score for USA Mobile Drug Testing is currently 55, which places the brand in the Moderate performance tier, a designation that reflects both the genuine opportunity within the mobile compliance testing category and the due diligence questions that remain open given current disclosure levels. Explore the complete USA Mobile Drug Testing franchise profile on PeerSense to access the full suite of independent franchise intelligence data.